UH3 Varenicline for Cannabis Use Disorder
Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults
Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults
Sponsor study identifier
interventional
174
1 country
2
Study Start
January 31, 2020
Actual (reported)Primary Completion
February 9, 2023
Actual (reported)Study Completion
December 1, 2023
Actual (reported)Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2023
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 6, 2019
Actual (reported)June 10, 2019
Actual (reported)January 31, 2020
Actual (reported)February 9, 2023
Actual (reported)December 1, 2023
Actual (reported)January 18, 2024
Actual (reported)Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions
Cannabis use reduction was measured by daily substance use logs/self-report and examined as the total number of use sessions reported at each weekly visit.
Treatment phase Weeks 6-12
Safety and Tolerability of Varenicline vs. Placebo When Used for Cannabis Use Disorder
12 weeks (across the active treatment period)
2 mg daily
2 mg daily
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Behavioral Health Services of Pickens County
Pickens, South Carolina, 29671, United States
Varenicline's efficacy for cannabis use disorder may vary by sex; however, this study was not powered to fully explore potential sex differences.
Aimee McRae-Clark, PharmD
Medical University of South Carolina
174 participants (actual enrollment reported by the registry).
First Submitted
June 6, 2019
First Posted
June 10, 2019
Study Start
January 31, 2020
Actual (reported)Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
Contact the study team to confirm eligibility.
Primary Completion
February 9, 2023
Actual (reported)Study Completion
December 1, 2023
Actual (reported)Last Updated
January 18, 2024
Results First Posted
January 18, 2024
Record last verified: 2023-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: